Dupilumab and prurigo nodularis-like phenotype in atopic dermatitis: our experience of efficacy

S. Ferrucci, S. Tavecchio, E. Berti, L. Angileri

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: Atopic dermatitis (AD) is a common chronic multifactorial dermatosis that can occur through different clinical phenotypes although all exhibit identical pathogenetic mechanisms such as the prurigo nodularis (PN)-like phenotype. Case Report: Here, we described 11 patients with PN-like AD treated with dupilumab, a human monoclonal IgG4 antibody that inhibits interleukin-4 (IL-4) and interleukin-13 (IL-13). Efficacy outcomes were performed at baseline, at first and fourth month after starting treatment. We collected different scores such as NRSi as well as IGA. At the same time, patient subjective benefits were analyzed through DLQI, POEM, and HADS scores. Quality of sleep was also recorded by NRSS. All patients showed rapid clinical improvement of cutaneous lesions and no other new lesions were reported during treatment. Reduction of daily itching was referred already after the first month of treatment. Conclusion: These results show the effectiveness of dupilumab in this clinical setting of AD, supporting this treatment as a valid therapeutic approach in difficult-to-treat-PN-like clinical presentation of AD.

Original languageEnglish
JournalJournal of Dermatological Treatment
DOIs
Publication statusAccepted/In press - Jan 1 2019

Fingerprint

Prurigo
Atopic Dermatitis
Phenotype
Therapeutics
Interleukin-13
Pruritus
Skin Diseases
Interleukin-4
Sleep
Immunoglobulin G
Monoclonal Antibodies
SAR231893
Skin

Keywords

  • atopic dermatitis
  • dupilumab
  • Prurigo nodularis

ASJC Scopus subject areas

  • Dermatology

Cite this

@article{50c991ea670c43e685d994540f7264ac,
title = "Dupilumab and prurigo nodularis-like phenotype in atopic dermatitis: our experience of efficacy",
abstract = "Background: Atopic dermatitis (AD) is a common chronic multifactorial dermatosis that can occur through different clinical phenotypes although all exhibit identical pathogenetic mechanisms such as the prurigo nodularis (PN)-like phenotype. Case Report: Here, we described 11 patients with PN-like AD treated with dupilumab, a human monoclonal IgG4 antibody that inhibits interleukin-4 (IL-4) and interleukin-13 (IL-13). Efficacy outcomes were performed at baseline, at first and fourth month after starting treatment. We collected different scores such as NRSi as well as IGA. At the same time, patient subjective benefits were analyzed through DLQI, POEM, and HADS scores. Quality of sleep was also recorded by NRSS. All patients showed rapid clinical improvement of cutaneous lesions and no other new lesions were reported during treatment. Reduction of daily itching was referred already after the first month of treatment. Conclusion: These results show the effectiveness of dupilumab in this clinical setting of AD, supporting this treatment as a valid therapeutic approach in difficult-to-treat-PN-like clinical presentation of AD.",
keywords = "atopic dermatitis, dupilumab, Prurigo nodularis",
author = "S. Ferrucci and S. Tavecchio and E. Berti and L. Angileri",
year = "2019",
month = "1",
day = "1",
doi = "10.1080/09546634.2019.1659479",
language = "English",
journal = "Journal of Dermatological Treatment",
issn = "0954-6634",
publisher = "Informa Healthcare",

}

TY - JOUR

T1 - Dupilumab and prurigo nodularis-like phenotype in atopic dermatitis

T2 - our experience of efficacy

AU - Ferrucci, S.

AU - Tavecchio, S.

AU - Berti, E.

AU - Angileri, L.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background: Atopic dermatitis (AD) is a common chronic multifactorial dermatosis that can occur through different clinical phenotypes although all exhibit identical pathogenetic mechanisms such as the prurigo nodularis (PN)-like phenotype. Case Report: Here, we described 11 patients with PN-like AD treated with dupilumab, a human monoclonal IgG4 antibody that inhibits interleukin-4 (IL-4) and interleukin-13 (IL-13). Efficacy outcomes were performed at baseline, at first and fourth month after starting treatment. We collected different scores such as NRSi as well as IGA. At the same time, patient subjective benefits were analyzed through DLQI, POEM, and HADS scores. Quality of sleep was also recorded by NRSS. All patients showed rapid clinical improvement of cutaneous lesions and no other new lesions were reported during treatment. Reduction of daily itching was referred already after the first month of treatment. Conclusion: These results show the effectiveness of dupilumab in this clinical setting of AD, supporting this treatment as a valid therapeutic approach in difficult-to-treat-PN-like clinical presentation of AD.

AB - Background: Atopic dermatitis (AD) is a common chronic multifactorial dermatosis that can occur through different clinical phenotypes although all exhibit identical pathogenetic mechanisms such as the prurigo nodularis (PN)-like phenotype. Case Report: Here, we described 11 patients with PN-like AD treated with dupilumab, a human monoclonal IgG4 antibody that inhibits interleukin-4 (IL-4) and interleukin-13 (IL-13). Efficacy outcomes were performed at baseline, at first and fourth month after starting treatment. We collected different scores such as NRSi as well as IGA. At the same time, patient subjective benefits were analyzed through DLQI, POEM, and HADS scores. Quality of sleep was also recorded by NRSS. All patients showed rapid clinical improvement of cutaneous lesions and no other new lesions were reported during treatment. Reduction of daily itching was referred already after the first month of treatment. Conclusion: These results show the effectiveness of dupilumab in this clinical setting of AD, supporting this treatment as a valid therapeutic approach in difficult-to-treat-PN-like clinical presentation of AD.

KW - atopic dermatitis

KW - dupilumab

KW - Prurigo nodularis

UR - http://www.scopus.com/inward/record.url?scp=85071970157&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071970157&partnerID=8YFLogxK

U2 - 10.1080/09546634.2019.1659479

DO - 10.1080/09546634.2019.1659479

M3 - Article

C2 - 31442084

AN - SCOPUS:85071970157

JO - Journal of Dermatological Treatment

JF - Journal of Dermatological Treatment

SN - 0954-6634

ER -